Individualizing cancer therapy.
Gertz
Morie A
MA
Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA. gertz.morie@mayo.edu
Tadmor
Tamar
T
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001897:Boronic Acids / Q000627:therapeutic use*; D000069286:Bortezomib; D019938:Cyclin D1 / Q000235:genetics* / Q000378:metabolism; D006801:Humans; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D057285:Precision Medicine; D011719:Pyrazines / Q000627:therapeutic use*; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D001897:Boronic Acids; C530104:CCND1 protein, human; D011719:Pyrazines; D019938:Cyclin D1; D000069286:Bortezomib